Chidamide augment sorafenib-derived anti-tumor activities in human osteosarcoma cells lines and xenograft mouse model

Previous studies have showed promising but short-lived activity of sorafenib in osteosarcoma treatments. Researches have suggested ameliorated sensitivity to standard dose of conventional cancer therapies in combination with histone deacetylase inhibitors (HDACis) through various mechanisms. Herein,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medical oncology (Northwood, London, England) London, England), 2022-05, Vol.39 (6), p.87
Hauptverfasser:	Yuan, Ying, Li, Daifeng, Hu, Xiang, Li, Yizhou, Yi, Wanrong, Li, Pengcheng, Zhao, Yong, Li, Zonghuan, Yu, Aiming, Jian, Chao, Yu, Aixi
Format:	Artikel
Sprache:	eng
Schlagworte:	Aminopyridines Animals Apoptosis Benzamides Bone cancer Bone Neoplasms - drug therapy Cell cycle Cell growth Cell Line, Tumor Hematology Heterografts Histone Deacetylase Inhibitors - pharmacology Humans Inhibitor drugs Internal Medicine Medicine Medicine & Public Health Mice Oncology Original Paper Osteosarcoma - drug therapy Pathology Sarcoma Sorafenib - pharmacology Sorafenib - therapeutic use Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!